You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Journal of Clinical Medicine
Download PDF
  • Review
  • Open Access

30 June 2022

Itch in Hidradenitis Suppurativa/Acne Inversa: A Systematic Review

,
,
,
,
,
,
,
,
and
1
Department of Dermatology, SMS Medical College and Hospital, Jaipur 302004, Rajasthan, India
2
Department of Dermatology, Venereology and Leprosy, Bharati Vidyapeeth (DTU) Medical College and Hospital, Pune 411043, Maharashtra, India
3
Department of Dermatology, Bangalore Medical College and Research Institute, Bangalore 560002, Karnataka, India
4
Department of Dermatology, Wayne State University, Detroit, MI 48202, USA
J. Clin. Med.2022, 11(13), 3813;https://doi.org/10.3390/jcm11133813
This article belongs to the Special Issue 10th Anniversary of JCM – New Era in Dermatology
Version Notes
Order Reprints
Review Reports

Abstract

Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory disease of the pilosebaceous unit leading to formation of painful, inflammatory nodules, abscesses and tunnels in apocrine gland-bearing areas of the skin. Pain and drainage are the most important symptoms associated with reduction of quality of life in HS. On the other hand, an overlooked symptom in quality of life studies is itch, despite the fact that several studies have reported its importance. Various theories have tried to explain the pathogenesis of itch in HS, such as the presence of mast cells in the cell infiltrates and elevated Ig E levels in the lesional skin. Smoking and advanced stage of disease have been found to be associated with increased intensity of itch. A PUBMED search was conducted to perform a systematic literature review using the term “hidradenitis suppurativa” [all fields], the keywords “pruritus”, “itching”, “itch” [all fields] and with “AND” as operator. Mast cells and mTor signaling were found to be raised in both lesional and perilesional skin. Itch as a presenting symptom has been found in 35–82.6% of patients across multiple studies. It often co-presents with pain and may be misinterpreted as burning, stinging, tickling, tweaking, prickling, etc. The presence of itch is associated with reduced quality of life, depression and impairment of social life. Brodalumab, a monoclonal antibody against IL-17A receptor, produced significant improvements in itch, pain, QoL and depression in patients with moderate to severe HS. Statins have shown some reduction in itch intensity score. Further studies are required to gain a better understanding of the etiopathogenesis and optimal therapeutic modalities for itch in HS that will allow clinicians to better address issue and reduce its impact on quality of life.

1. Introduction

Hidradenitis suppurativa/acne inversa (HS) is a chronic debilitating inflammatory skin disease of the pilosebaceous unit [1]. It is characterized by recurrent nodules, abscesses and draining tunnels, which lead to scarring, and occurs in areas rich in apocrine glands [2]. It is a commonly under-diagnosed and under-treated disease [3]. Due to its chronic and relapsing course, it has a grave impact on quality of life (QoL) [4]. Dysregulated immunity, genetic predisposition, smoking and obesity are some of the risk factors found to initiate perifollicular inflammation, which ultimately leads to the formation of painful inflamed lesions [5,6].
The clinical features reported to most reduce the QoL of HS patients are pain and malodorous purulent discharge from skin tunnels. In a study conducted on 1795 subjects, pain was found in 83.6% cases [7]. Few authors, however, have reported in detail prodromal symptoms, such as a burning or stinging sensation, itch, warmth and/or hyperhidrosis [8]. Amongst these prodromal symptoms, itch has been described as an important HS symptom in various studies and has long been overlooked. Thus, we performed a systematic review of the literature to find the prevalence, severity and probable causes of itch in HS.

2. Method

A PUBMED search was done for systematic review of literature using the term “hidradenitis suppurativa” [all fields]; the keywords “pruritus”, “itching” and “itch” [all fields]; and “AND” as operator.
The search yielded 105 articles; whereas after the removal of duplicates, 48 articles were left. A total of 28 articles were excluded due to eligibility. Finally, 20 articles were selected for the study. The selection of articles was performed independently by SBL and NSS. All articles were reviewed by the senior author, VRS, who also had the final decision in case of disagreement between the initial selectors (Figure 1 and Table 1).
Figure 1. PRISMA flowchart of the selected studies, with criteria and numbers of studies.
Table 1. Eligible articles based on inclusion criteria.

3. Epidemiology

The presence of itch in patients with HS ranged from 62.1% to 77.5% in the selected studies [9,19,25]. The severity of itch has also been assessed in these studies, mostly through a 11-point numerical rating scale (NRS) ranging from 0 to 10, with 0 representing no itch and 10 representing severe itch affecting daily functions and sleep. The NRS score among the patients varied from 4.5 ± 3.5 to 5.4 ± 2.5 points, indicating that the itch in HS is mostly mild to moderate [14,25]. Matusiak et al. and Fernandez et al. found the intensity of itch to be positively correlated with smoking and severity of disease, while, in Molina-Levya et al., the correlation between the two was statistically insignificant [9,14,19]. One study also observed positive association with female sex, number of affected sites and intensity of drainage. In the same study, the presence of Crohn’s disease and acneiform eruptions were also found to increase itch. However, if the patients were on statin treatment, itch seemed to be less intense [14].
Itch in HS has also been found to adversely affect QoL. In a study by Riis et al., a significant association was found between loss of utility and itch [26]. A study by Molina-Leyva et al. on 233 patients also observed that itch caused QoL impairment [14]. Vossen et al. noted that itch affected sleep in 70% and daily activities in 53% of HS patients [25]. A study assessing the influence of itch and pain in HS by using the Athens Insomnia Scale (AIS) and Pittsburgh Sleep Quality Index (PSQI), found that sleep disturbance was more common in patients than insomnia. It affected sleep latency, habitual sleep efficiency, sleep disturbances, sleep duration and daytime dysfunction compared with controls [12,15,21]. In another study with 103 patients with HS, 97% had itching and 62% had pain, and 60% of patients had both symptoms together. A positive correlation was found between itching and impaired QoL. Itch was associated with significant influence on frequency of insomnia [17].

4. Etiopathogenesis

The exact pathogenesis of itch in HS is not understood. In the studies by the Rotterdam group (van der Zee et al. [29]; Vossen et al. [25]) histopathological observations were reported in 10 specimens obtained after the surgical excision of HS lesions. They found that tryptase-positive mast cells were significantly increased in both lesional and perilesional skin. They hypothesized the increased number of mast cells to be a possible cause for the reported itch, along with increased serum IgE levels, which may lead to the degranulation of the mast cells, releasing histamine and other mediators, such as proteases.
De Vita et al. [22]. commented that alteration in mammalian target of rapamycin (mTOR) signaling through the mTORC1 pathway could be an alternate hypothesis. Raised levels of mTOR both in lesional and non-lesional skin have been demonstrated in HS, with statistically significant correlation between mTOR gene expression and disease severity [30].
Pascual et al. [31]. measured the level of IgE antibodies in 99 patients with HS. They found elevated levels of IgE in 37.4% patients, with a mean of 186.4 IU/mL and up to a maximum of 2379 IU/mL. The levels were found to be higher in smokers. They concluded that the elevated IgE and an increased infiltration of mast cells in HS could trigger degranulation, thereby releasing histamine and causing itch.
List et al. studied biopsy specimens from HS lesions and perilesional skin from 34 HS patients. They found a larger number of mast cells in lesional skin, with Toluidine blue and CD117 staining, which correlated with itch disease severity by Sartorius score when adjusted to age and sex. They also found a positive correlation between mast cell count and HS activity, suggesting an important relationship between mast cells and HS [16]. Mast cells acts synergistically with other immune cells and secrete multiple proinflammatory cytokines [14,16].
Vossen et al. [25] found an influx of eosinophilic granulocytes, along with a perineural infiltrate comprised of neutrophils and lymphocytes in both lesional and perilesional skin. They observed small fiber neuropathy due to scar formation, suggesting neurogenic inflammation as a probable factor causing itch. This theory of perineural infiltrate and presence of mast cells causing itch was also supported by Matusiak et al. [19].
Mediators of pain and itch overlap in chronic inflammatory conditions [20,32]. Fernandez et al. [9] observed that 74.9% of HS patients experienced both pain and itch. They suggested that, since C-fibres carry sensation for both itch and pain via lateral spinothalamic tract to the thalamus, patients might not be able to accurately distinguish both sensations.
A-fibres, which are sensitive to histaminergic and non-histaminergic stimuli, can be responsible for the induction of itch in HS [22]. A study done by Obara et al. in mice for generalized itch found small diameter A-delta nociceptors with activated mTOR. This activated form of mTOR maintained the excitability of the A-fibers. The inhibition of mTORC1 pathway led to inhibited itch stimuli in mice [33]
Chemokine CCL-26 (eotaxin-3) has recently been identified as an important mediator of inflammation in HS. It has also been found to be significantly elevated in atopic dermatitis and cutaneous T-cell lymphoma, wherein it is likely to mediate the infiltration of eosinophils, basophils and T cells. Both conditions are also associated with high itch scores [18,34].

5. Clinical Features

Itch is an important symptom in HS [17]. In several studies, itch was reported to be more intensive in the inguinal region and buttocks than in the axillae. In a study on perianal HS, itch was registered in 10% of patients [35]. The characteristics of itch were studied in detail by Matusiak et al. [19]. They observed that 34.9% patients experienced itch every day, 32.6% a few times a week and 30.2% experienced itch once a month. Itch lasted for less than 10 min in 79.1% of the patients. The primary sensation of itch was described as burning (46.5%), stinging (25.6%), tickling (18.6%), tweaking (16.3%) and prickling (14%) and so on. Excoriation marks were seen in 14% of the patients. Itching was present in the morning and afternoon in 16.3% of the patients, the evening in 51.2% and the night in 18.6%. Sweating, heat, hot bath and physical activity exacerbated itch.
In a retrospective data analysis conducted on 145 patients, itch was reported by 82.1% of the patients and correlated with Hurley stage [28]. Vossen et al. [25] found a similar correlation with Hurley stages along with the number of inflamed areas. In contrast, Pascual et al. [13] found a correlation with active smoking but not with Hurley stages or number of inflamed areas.
In a study evaluating the prodromal symptoms in HS, 20% patients experienced itching at least 24 h before the onset of any visible signs [23]. Through a questionnaire, 26.3% of patients with umbilical flares of HS experienced erythema and itching with no discharge, while 73.7% experienced malodorous or bloody discharge from the umbilicus [24].
Esmann et al. [11] studied the psychosocial impact of HS and found that pain, itching, odor and scars led to irritation, anger, sadness, worry and depression. Odorous draining lesions, severe pain and itch limited patients’ social interaction.

6. Treatment

Studies to assess the efficacy of various treatment modalities in HS associated itch are yet to be conducted. Few authors have associated pain with itch, and the alleviation of pain may reduce itch [9]. Many topical, as well as oral, therapies have been suggested to manage pain in HS [27]. Itch can be associated with abscesses and nodules; thus treatment of these lesions may alleviate itch [21].
Brodalumab, a monoclonal antibody against IL-17A receptor, produced significant improvements in itch, pain, QoL and depression in patients with moderate to severe HS [36]. Statins, used for controlling dyslipidemia, have shown some reduction in itch intensity score, probably due to their anti-inflammatory properties and warrants further evaluation [14].
JAK inhibitors have recently been used in treating HS successfully. INCB54707, a experimental molecule which is 52 times more selective for JAK1 than JAK2, has been tried in two multicentric phase 2 studies, wherein a single dose of 90mg oral treatment resulted in a hidradenitis suppurativa clinical response (HiSCR) (defined as at least a 50% reduction in inflammatory lesion count with no increase in abscesses or draining fistulae compared to baseline) score of 88% at week 8. A dose-dependent significant improvement in hidradenitis suppurativa quality of life scores was documented in response to the JAK1 inhibitor [10].
Recent studies have shown that JAK inhibitors can reduce itch symptoms in patients with atopic dermatitis. It is suggested that JAK inhibitors act by blocking neuronal JAK1 signaling in non-inflammatory settings. JAK inhibition with tofacitinib were tried in five patients with severe chronic inflammatory pruritus off-label; all patients showed reduced itch scores, despite having failed to respond to multiple other treatments. These findings suggest the potential use of JAK inhibitors in alleviating itch symptoms in HS [37].
Studies have demonstrated the efficacy of metformin in treating recalcitrant HS. Metformin at a dose of 500 mg 3 times daily for 24 weeks resulted in an average reduction in Sartorius score by 12.78 (p = 0.0001) at 24 weeks, which was statistically significant. Improvement in DLQI was significant in 64% of patients. In addition, depression, which was earlier noted to be severe in 11 patients, became nonsevere in 7 of the 11 patients [38]. Arun and Loffeld reported a case of HS with type 2 diabetes that responded exceedingly well to metformin. After four months of treatment, the sinus tracts and leaking abscesses on the patient’s left axilla showed marked resolution, with considerable pain relief [39]. The mechanism by which metformin acts in HS is still not known. However, metformin is known to activate the AMPK pathway through LKB1, eventually causing the inhibition of the mTOR pathway. This pathway is a key factor in mediating itch in pruritus, and metformin may additionally improve the DQLI of patients by itch alleviation [40].

7. Conclusions

Despite a lack of complete understanding of itch in HS, it is an important aspect of the disease, reported in 62% to 75% of patients. Further study to gain a better understanding of the etiopathogenesis and optimal therapeutic modalities for itch in HS will allow clinicians to better address this aspect of the disease and reduce its impact on quality of life.

Author Contributions

Writing and revising the manuscript, P.A. and C.C.Z.; Review and revising the manuscript, S.B.L., N.S.S., P.K., S.D., A.G.O.-L., T.T., J.C.S., C.C.Z. and S.G.; Conception, writing, review and revising the manuscript, M.G. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the Research Grant from Wrocław Medical University (number: SUBZ.C260.22.056).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany are health care providers of the European Reference Network for Rare and Complex Skin Diseases (ERN Skin-ALLOCATE Skin group).

Conflicts of Interest

C.C.Z. reports consultancy/advisory board/speaker disease-relevant honoraria from Incyte, InflaRx, Janssen, Novartis, Regeneron, and UCB. His departments have received grants from AbbVie, Boehringer Ingelheim, InflaRx, Novartis, and UCB. C.C.Z. declares that none of the mentioned conflicts of interest had any influence to this manuscript.

References

  1. Ralf Paus, L.; Kurzen, H.; Kurokawa, I.; Jemec, G.B.; Emtestam, L.; Sellheyer, K.; Giamarellos-Bourboulis, E.J.; Nagy, I.; Bechara, F.G.; Sartorius, K.; et al. What causes hidradenitis suppurativa? Exp. Dermatol. 2008, 17, 455–472. [Google Scholar] [PubMed]
  2. Emtestam, L.; Desai, N.; Hunger, R.; Zouboulis, C.C.; Ioannides, D.; Van Der Zee, H.H.; Prens, E.P.; E Jemec, G.B.; Schneider-Burrus, S.; Revuz, J.; et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 619–644. [Google Scholar]
  3. Nguyen, T.V.; Damiani, G.; Orenstein, L.A.; Hamzavi, I.; Jemec, G.B. Hidradenitis suppurativa: An update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 50–61. [Google Scholar] [CrossRef] [PubMed]
  4. Chernyshov, P.V.; Zouboulis, C.C.; Tomas-Aragones, L.; Jemec, G.B.; Svensson, A.; Manolache, L.; Tzellos, T.; Sampogna, F.; Pustisek, N.; Van der Zee, H.H.; et al. Quality of life measurement in hidradenitis suppurativa: Position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J. Eur. Acad. Derm. Venereol. 2019, 33, 1633–1643. [Google Scholar] [CrossRef] [Green Version]
  5. Yazdanyar, S.; Jemec, G.B.E. Hidradenitis suppurativa: A review of cause and treatment. Curr. Opin. Infect Dis. 2011, 24, 118–123. [Google Scholar] [CrossRef]
  6. Vinkel, C.; Thomsen, S.F. Hidradenitis Suppurativa: Causes, Features, and Current Treatments. J. Clin. Aesthet. Dermatol. 2018, 11, 17–23. [Google Scholar]
  7. Krajewski, P.K.; Matusiak, Ł.; von Stebut, E.; Schultheis, M.; Kirschner, U.; Nikolakis, G.; Szepietowski, J.C. Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1795 Patients. Acta Derm. Venereol. 2021, 101, adv00364. [Google Scholar]
  8. Napolitano, M.; Megna, M.; Timoshchuk, E.A.; Patruno, C.; Balato, N.; Fabbrocini, G.; Monfrecola, G. Hidradenitis suppurativa: From pathogenesis to diagnosis and treatment. Clin.Cosmet. Investig. Dermatol. 2017, 10, 105–115. [Google Scholar] [CrossRef] [Green Version]
  9. Fernandez, J.M.; Rizvi, O.H.; Marr, K.D.; Price, K.N.; Hendricks, A.J.; Hsiao, J.L.; Shi, V.Y. Itch and pain by lesion morphology in hidradenitis suppurativa patients. Int. J. Dermatol. 2021, 60, e56–e59. [Google Scholar] [CrossRef]
  10. Alavi, A.; Hamzavi, I.; Brown, K.; Santos, L.L.; Zhu, Z.; Liu, H.; Howell, M.D.; Kirby, J.S. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: Results from two phase II studies. Br. J. Dermatol. 2022, 186, 803–813. [Google Scholar] [CrossRef]
  11. Esmann, S.; Jemec, G.B. Psychosocial impact of hidradenitis suppurativa: A qualitative study. Acta Derm. Venereol. 2011, 91, 328–332. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Mac Mahon, J.; Kirthi, S.; Byrne, N.; O’Grady, C.; Tobin, A.M. An update on health-related quality of life and patient-reported outcomes in hidradenitis suppurativa. Patient Relat. Outcome Meas. 2020, 11, 21. [Google Scholar] [CrossRef] [PubMed]
  13. Pascual, J.C.; Alvarez, P.; Encabo, B.; González, I.; Hispán, P.; Poveda, I.; Romero, D. Comment on: “Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study”. Am. J. Clin. Dermatol. 2017, 18, 705–706. [Google Scholar] [CrossRef] [PubMed]
  14. Molina-Leyva, A.; Cuenca-Barrales, C. Pruritus and Malodour in Patients with Hidradenitis Suppurativa: Impact on Quality of Life and Clinical Features Associated with Symptom Severity. Dermatology 2020, 236, 59–65. [Google Scholar] [CrossRef] [PubMed]
  15. Kaaz, K.; Szepietowski, J.C.; Matusiak, Ł. Sleep quality among adult patients with chronic dermatoses. Adv. Dermatol. Allergol./Postȩpy Dermatol. I Alergol. 2019, 36, 659. [Google Scholar] [CrossRef] [PubMed]
  16. List, E.K.; Pascual, J.C.; Zarchi, K.; Nürnberg, B.M.; Jemec, G.B. Mast cells in hidradenitis suppurativa: A clinicopathological study. Arch. Dermatol. Res. 2019, 311, 331–335. [Google Scholar] [CrossRef]
  17. Posso-De Los Rios, C.J.; Sarfo, A.; Ghias, M.; Alhusayen, R.; Hamzavi, I.; Lowes, M.A.; Alavi, A. Proceeding report of the third symposium on Hidradenitis Suppurativa advances (SHSA) 2018. Exp. Dermatol. 2019, 28, 769–775. [Google Scholar] [CrossRef]
  18. Nakahigashi, K.; Doi, H. Otsuka e PGD2 induces eotaxin-3 via PPARγ from sebocytes: A possible pathogenesis of eosinophilic pustular folliculitis. J. Allergy Clin. Immunol. 2012, 129, 536–543, Correction in 2014, 133, 604. [Google Scholar] [CrossRef]
  19. Matusiak, Ł.; Szczęch, J.; Kaaz, K.; Lelonek, E.; Szepietowski, J.C. Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa. Acta Derm. Venereol. 2018, 98, 191–194. [Google Scholar] [CrossRef] [Green Version]
  20. Vekic, D.A.; Cains, G.D. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 2. Australas. J. Dermatol. 2018, 59, 261–266. [Google Scholar] [CrossRef]
  21. Kaaz, K.; Szepietowski, J.C.; Matusiak, Ł. Influence of Itch and Pain on Sleep Quality in Patients with Hidradenitis Suppurativa. Acta Derm. Venereol. 2018, 98, 757–761. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. De Vita, V.; Matusiak, Ł.; Szepietowski, J.C. Comment on: “Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study”. Am. J. Clin. Dermatol. 2017, 18, 707–708. [Google Scholar] [CrossRef] [PubMed]
  23. Ring, H.C.; Theut Riis, P.; Zarchi, K.; Miller, I.M.; Saunte, D.M.; Jemec, G.B. Prodromal symptoms in hidradenitis suppurativa. Clin. Exp. Dermatol. 2017, 42, 261–265. [Google Scholar] [CrossRef] [PubMed]
  24. Andersen, R.K.; Jemec, G.B.; Saunte, D.M. Umbilical Hidradenitis Suppurativa Symptoms: A Case Series and Review of the Literature. Acta Dermatovenerol. Alp. Pannonica Et Adriat. 2020, 29, 3–6. [Google Scholar]
  25. Vossen, A.R.J.V.; Schoenmakers, A.; van Straalen, K.R.; Prens, E.P.; Van Der Zee, H.H. Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study. Am. J. Clin. Dermatol. 2017, 18, 687–695. [Google Scholar] [CrossRef] [Green Version]
  26. Riis, P.T.; Vinding, G.R.; Ring, H.C.; Jemec, G.B. Disutility in Patients with Hidradenitis Suppurativa: A Cross-sectional Study Using EuroQoL-5D. Acta Derm. Venereol. 2016, 96, 222–226. [Google Scholar] [CrossRef] [Green Version]
  27. Horváth, B.; Janse, I.C.; Sibbald, G.R. Pain management in patients with hidradenitis suppurativa. J. Am. Acad. Dermatol. 2015, 73, S47–S51. [Google Scholar] [CrossRef]
  28. McKenzie, S.A.; Harview, C.L.; Truong, A.K.; Grogan, T.R.; Shi, V.Y.; Bennett, R.G.; Hsiao, J.L. Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: Correlation with Hurley stage. Dermatol. Online J. 2020, 26, 13030. [Google Scholar] [CrossRef]
  29. Van der Zee, H.; de Ruiter, L.; Boer, J.; Broecke, D.V.D.; Hollander, J.D.; Laman, J.; Prens, E. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br. J. Dermatol. 2012, 166, 98–106. [Google Scholar] [CrossRef]
  30. Monfrecola, G.; Balato, A.; Caiazzo, G.; De Vita, V.; Di Caprio, R.; Donnarumma, M.; Lembo, S.; Fabbrocini, G. Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: A possible metabolic loop. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 1631–1633. [Google Scholar] [CrossRef] [Green Version]
  31. Pascual, J.C.; Garcia-Martinez, F.J.; Martorell, A.; González, I.; Hispan, P. Increased total serum IgE levels in moderate-to-severe hidradenitis suppurativa. Br. J. Dermatol. 2016, 175, 1101–1102. [Google Scholar] [CrossRef] [PubMed]
  32. Schmelz, M. Itch and pain. Neurosci. Biobehav. Rev. 2010, 34, 171–176. [Google Scholar] [CrossRef] [PubMed]
  33. Obara, I.; Medrano, M.C.; Signoret-Genest, J.; Jiménez-Díaz, L.; Géranton, S.M.; Hunt, S.P. Inhibition of the mammalian target of rapamycin complex 1 signaling pathway reduces itch behaviour in mice. Pain 2015, 156, 1519–1529. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Vossen, A.R.J.V.; van der Zee, H.H.; Tsoi, L.C.; Xing, X.; Devalaraja, M.; Gudjonsson, J.E.; Prens, E.P. Novel cytokine and chemokine markers of hidradenitis suppurativa reflect chronic inflammation and itch. Allergy 2019, 74, 631–634. [Google Scholar] [CrossRef]
  35. Wiltz, O.; Schoetz, D.J.; Murray, J.J.; Roberts, P.L.; Coller, J.A.; Veidenheimer, M.C. Perianal hidradenitis suppurativa. Dis. Colon Rectum 1990, 33, 731–734. [Google Scholar] [CrossRef]
  36. Frew, J.W.; Navrazhina, K.; Grand, D.; Sullivan-Whalen, M.; Gilleaudeau, P.; Garcet, S.; Ungar, J.; Krueger, J.G. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study. J. Am. Acad. Dermatol. 2020, 83, 1341–1348. [Google Scholar] [CrossRef]
  37. Bordon, Y. JAK in the itch. Nat. Rev. Drug Discov. 2017, 16, 753. [Google Scholar] [CrossRef]
  38. Verdolini, R.; Clayton, N.; Smith, A.; Alwash, N.; Mannello, B. Metformin for the treatment of hidradenitis suppurativa: A little help along the way. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 1101–1108. [Google Scholar] [CrossRef]
  39. Arun, B.; Loffeld, A. Long-standing hidradenitis suppurativa treated effectively with metformin. Clin. Exp. Dermatol. 2009, 34, 920–921. [Google Scholar] [CrossRef]
  40. Clements, A.; Gao, B.; Yeap, S.H.; Wong, M.K.; Ali, S.S.; Gurney, H. Metformin in prostate cancer: Two for the price of one. Ann. Oncol. 2011, 22, 2556–2560. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
Characteristics and Outcomes of Patients Consulted by a Multidisciplinary Pulmonary Embolism Response Team: 5-Year Experience
Previous
Prevalence and Clinical Conditions Related to Sarcopaenia among Older Persons Living in the Community
Next